Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial

We recently compiled a list of 11 Best Future Stocks to Buy Now. Viking Therapeutics, Inc. stands third on our list.

Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharma company developing treatments for metabolic and endocrine disorders, including obesity, NASH, and rare diseases like X-linked adrenoleukodystrophy (X-ALD). Its lead candidate, VK2735—a dual GLP-1/GIP receptor agonist- is now in Phase 3 VANQUISH trials for obesity and obesity with type 2 diabetes, following strong Phase 1 and 2 results demonstrating significant weight loss and safety, making it one of the best growth stocks in the biotech sector.

Viking Therapeutics, Inc. (NASDAQ:VKTX) has also completed enrollment in a Phase 2 trial for an oral version of VK2735, with top-line results expected in the second half of 2025. If successful, the oral formulation could offer a more convenient alternative to injectable obesity drugs.

The company is further expanding its pipeline with a novel amylin agonist program aimed at metabolic disorders, expecting to file an IND by Q4 2025. Additionally, VK2809, a thyroid hormone receptor beta agonist for NASH, has shown positive Phase 2b results. The business is also advancing VK0214 for X-ALD and other programs targeting lipid metabolism.

Viking Therapeutics, Inc. (VKTX) Nears Obesity Drug Breakthrough with Phase 3 VK2735 Trial

A scientist in the lab, researching the development of biopharmaceutical monoclonal antibody drugs.

With a robust pipeline and $808 million in cash (as of June 2025), Viking Therapeutics, Inc. (NASDAQ:VKTX) is well-positioned to fund upcoming milestones. The Phase 3 VK2735 trials and pending oral trial results are key near-term catalysts.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.